Evidence map›Paper›PMID 36309395›Full record

ArticleIn vivo (Athens, Greece)

A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy.

Eiki Yamasaki, Fukutaro Shimamoto, Hiroki Nishikawa, Masahiro Goto, Mitsuhiko Iwamoto, Kosei Kimura, Akira Ukimura, Naofumi Oosaka, Kohei Taniguchi, Fumihito Ono and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.International journal of molecular sciences · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Eiki YamasakiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Fukutaro ShimamotoCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Hiroki NishikawaSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; nishikawa_6392_0207@yahoo.co.jp.
Masahiro GotoCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Mitsuhiko IwamotoDepartment of Breast Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kosei KimuraDepartment of Breast Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Akira UkimuraThird Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Naofumi OosakaDepartment of Central Clinical Laboratory, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kohei TaniguchiTranslational Research Program, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Fumihito OnoTranslational Research Program, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Tetsuji TerazawaCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Ken AsaishiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Takako IkegamiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kazuhisa UchiyamaDean, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Shiro NakamuraSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kazuhide HiguchiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Osaka University of Pharmaceutical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). PATIENTS AND

methodsCOVID-19 anti-spike protein antibody levels were measured before the first BNT162b2 vaccination, just before the second BNT162b2 vaccination, one month after the second BNT162b2 vaccination, and 3 months after the second BNT162b2 vaccination. Anti-spike protein antibody seropositivity was set at ≥0.8 U/ml.

resultsColorectal cancer was the most commonly observed primary disease (36.5%). ECOG-PS 0 was observed in the majority (52.4%) of patients. The overall response rate and the median (range) anti-spike protein antibody levels in the whole cohort at 3 months after the second BNT162b2 vaccination were 98.4% (62/63) and 206 (0.4-3,813) U/ml. None of the patients required postponement or discontinuation of systemic chemotherapy because of an adverse reaction.

conclusionThe BNT162b vaccine in solid cancer patients undergoing systemic chemotherapy is effective and safe.

Indexed as

COVID-19NeoplasmsVaccinesAntibodies, ViralBNT162 VaccineHumansProspective StudiesAntibodies, ViralBNT162 VaccineVaccinesadvanced cancerBNT162b2 vaccineefficacysafetysystemic chemotherapy

Identifiers

PMID36309395
PMCPMC9677789
OpenAlexW4307845224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.